James Simon, APRN
Endocrinology, Diabetes & Metabolism · Tampa, FLNPI 1982263760
Payments from drug & device makers
Across 84 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$337
- Xeris Pharmaceuticals, Inc.$177
- Dexcom, Inc.$173
- Lifescan, Inc.$148
- Abbott$145
- Corcept Therapeutics$111
- plus $567 from 14 others
What the payments were for
- Food & beverage$1,659100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 18 | $337 |
| Xeris Pharmaceuticals, Inc. | 11 | $177 |
| Dexcom, Inc. | 8 | $173 |
| Lifescan, Inc. | 6 | $148 |
| Abbott | 9 | $145 |
| Corcept Therapeutics | 5 | $111 |
| Bayer | 3 | $78 |
| Recordati_rare_diseases_inc. | 3 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $67 |
| Amneal Pharmaceuticals LLC | 3 | $66 |
| Nevro Corp. | 2 | $48 |
| Antares Pharma, Inc. | 2 | $38 |
| Amgen | 2 | $36 |
| Medtronic | 2 | $33 |
| AstraZeneca | 2 | $28 |
| Kyowa Kirin, Inc. | 1 | $26 |
| Novo Nordisk | 1 | $24 |
| IBSA Pharma Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $18 |
| Insulet Corporation | 1 | $16 |
How this compares
$1,659 in reported general payments places this provider in the 35th percentile of 586 endocrinology, diabetes & metabolism providers in Florida.
See all endocrinology, diabetes & metabolism providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tresiba Flextouch U-200Insulin Degludec | 15 | $21,310 |
| Morphine Sulfate | 24 | $233 |
| Atorvastatin Calcium | 13 | $158 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Tampa
- Andrew HenryTampa$929K
- Manuel Sainz de la PenaTampa$247K
- Yuvraj KumbkarniTampa$189K
- Richard PratleyOrlando$9.2M
- Jose MandryOcoee$9.1M
- Steven SmithOrlando$7.9M
- Barry HorowitzWest Palm Beach$7.1M
- Tina ThethiOrlando$3.8M
- David SuttonJacksonville$3.1M
- Lorena Lewy-AlterbaumHollywood$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.